Want to see PMVP full AI Analyst Report?
Top Page
PMV Pharmaceuticals
(NASDAQ:PMVP)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-10.71% Downside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance (pre-revenue, sizable losses, and heavy cash burn) and bearish technical conditions (below major moving averages with negative MACD). Governance-related corporate news is a modest positive, while valuation signals are limited due to the company’s loss-making profile and lack of dividend data.
Positive Factors
Low debt burden
PMV's minimal reported debt (≈$0.3M TTM) materially reduces solvency risk for a cash-burning biotech. Low leverage provides durable financial flexibility to pursue R&D, licensing or strategic options without being constrained by interest burdens over the next several quarters.
Negative Factors
High cash burn / negative cash flow
Sustained TTM operating and free cash outflows near -$75M signal entrenched cash burn. This persistent negative cash generation increases reliance on external financing, raising dilution and funding-risk over the coming quarters absent partner receipts or significant cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Low debt burden
PMV's minimal reported debt (≈$0.3M TTM) materially reduces solvency risk for a cash-burning biotech. Low leverage provides durable financial flexibility to pursue R&D, licensing or strategic options without being constrained by interest burdens over the next several quarters.
Read all positive factors
PMV Pharmaceuticals (PMVP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.46M
Dividend YieldN/A
Average Volume (3M)350.98K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue GrowthN/A
EPS Growth-26.14%
CountryUS
Employees47
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding53,331,764
10 Day Avg. Volume211,843
30 Day Avg. Volume350,983
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-300.42
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$4.50Price Target Upside301.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
PMV Pharmaceuticals Business Overview & Revenue Model
Company Description
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a s...
How the Company Makes Money
PMV Pharmaceuticals is a clinical-stage biopharmaceutical company and, as such, it typically does not generate recurring product sales revenue because it does not have broadly marketed, commercial-stage drugs. Its potential and/or historical sourc...
PMV Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -66.00K | 0.00 | -1.14M | -1.26M | -650.00K | -1.28M |
| EBITDA | -78.19M | -79.78M | -73.67M | -67.70M | -72.68M | -56.54M |
| Net Income | -78.34M | -77.74M | -58.71M | -68.96M | -73.32M | -57.85M |
Balance Sheet | ||||||
| Total Assets | 96.56M | 116.56M | 191.29M | 252.15M | 270.31M | 331.57M |
| Cash, Cash Equivalents and Short-Term Investments | 93.55M | 112.94M | 169.45M | 203.06M | 241.05M | 297.16M |
| Total Debt | 293.00K | 838.00K | 1.19M | 13.29M | 13.98M | 11.19M |
| Total Liabilities | 8.60M | 11.85M | 15.21M | 26.46M | 24.28M | 23.01M |
| Stockholders Equity | 87.97M | 104.71M | 176.08M | 225.69M | 246.03M | 308.56M |
Cash Flow | ||||||
| Free Cash Flow | -75.02M | -73.61M | -51.94M | -56.62M | -71.74M | -47.92M |
| Operating Cash Flow | -74.99M | -73.58M | -51.28M | -55.66M | -63.76M | -46.57M |
| Investing Cash Flow | 62.28M | 70.17M | 53.35M | -50.55M | -1.37M | -143.58M |
| Financing Cash Flow | 495.00K | 505.00K | 313.00K | 35.58M | 958.00K | 2.02M |
PMV Pharmaceuticals Technical Analysis
Neutral
1.12
Price Trends
1.27
Negative
1.30
Negative
1.30
Negative
Market Momentum
-0.03
Negative
51.26
Neutral
56.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMVP, the sentiment is Neutral. The current price of 1.12 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.27, and below the 200-day MA of 1.30, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.26 is Neutral, neither overbought nor oversold. The STOCH value of 56.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PMVP.
PMV Pharmaceuticals Risk Analysis
PMV Pharmaceuticals disclosed 77 risk factors in its most recent earnings report. PMV Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMV Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $379.17M | -0.93 | -94.90% | ― | -71.26% | -300.04% | |
49 Neutral | $74.64M | -3.41 | -201.43% | ― | ― | 33.86% | |
46 Neutral | $39.78M | -13.66 | -92.03% | ― | -100.00% | -170.04% | |
45 Neutral | $63.46M | -0.87 | -68.98% | ― | ― | -26.14% | |
44 Neutral | $348.85M | -4.65 | -118.24% | ― | 138.86% | 42.14% |
* Healthcare Sector Average
PMVP
PMV Pharmaceuticals
1.29
0.23
21.70%
XFOR
X4 Pharmaceuticals
4.23
2.33
122.63%
ABVC
ABVC BioPharma
1.57
-0.65
-29.28%
PRLD
Prelude Therapeutics
4.93
4.12
508.64%
GANX
Gain Therapeutics
1.98
0.18
10.00%
IMMX
Immix Biopharma
10.49
8.42
406.76%
PMV Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
PMV Pharmaceuticals Shareholders Back Directors and Governance Matters
Positive
Jun 5, 2026
On June 4, 2026, PMV Pharmaceuticals held its virtual 2026 Annual Meeting of Stockholders, where shareholders elected David H. Mack, Ph.D., and Laurie Stelzer as Class III directors to serve until the 2029 annual meeting, reinforcing continuity in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.